000179478306/302024Q1FALSEP1YP1Y.333.041600017947832023-07-012023-09-3000017947832023-10-31xbrli:shares00017947832023-09-30iso4217:USD00017947832023-06-30iso4217:USDxbrli:shares0001794783us-gaap:ServiceMember2023-07-012023-09-300001794783us-gaap:ServiceMember2022-07-012022-09-300001794783slqt:PharmacyMember2023-07-012023-09-300001794783slqt:PharmacyMember2022-07-012022-09-300001794783us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300001794783us-gaap:ProductAndServiceOtherMember2022-07-012022-09-3000017947832022-07-012022-09-300001794783us-gaap:CommonStockMember2023-06-300001794783us-gaap:AdditionalPaidInCapitalMember2023-06-300001794783us-gaap:RetainedEarningsMember2023-06-300001794783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001794783us-gaap:RetainedEarningsMember2023-07-012023-09-300001794783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001794783us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001794783us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001794783us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001794783us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001794783us-gaap:CommonStockMember2023-09-300001794783us-gaap:AdditionalPaidInCapitalMember2023-09-300001794783us-gaap:RetainedEarningsMember2023-09-300001794783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001794783us-gaap:CommonStockMember2022-06-300001794783us-gaap:AdditionalPaidInCapitalMember2022-06-300001794783us-gaap:RetainedEarningsMember2022-06-300001794783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000017947832022-06-300001794783us-gaap:RetainedEarningsMember2022-07-012022-09-300001794783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001794783us-gaap:CommonStockMember2022-07-012022-09-300001794783us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001794783us-gaap:CommonStockMemberus-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001794783us-gaap:AdditionalPaidInCapitalMemberus-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001794783us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001794783us-gaap:CommonStockMember2022-09-300001794783us-gaap:AdditionalPaidInCapitalMember2022-09-300001794783us-gaap:RetainedEarningsMember2022-09-300001794783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000017947832022-09-300001794783slqt:ExpressMedPharmaceuticalIncMember2021-04-30xbrli:pure0001794783slqt:ExpressMedPharmaceuticalIncMembersrt:MaximumMember2021-04-302021-04-300001794783slqt:ExpressMedPharmaceuticalIncMember2021-04-302021-04-300001794783slqt:ExpressMedPharmaceuticalIncMember2023-07-012023-09-30slqt:provision0001794783slqt:ExpressMedPharmaceuticalIncMember2023-06-300001794783slqt:ExpressMedPharmaceuticalIncMember2022-07-012023-06-300001794783slqt:SeniorSegmentMemberslqt:ExpressMedPharmaceuticalIncMember2021-04-300001794783slqt:ExpressMedPharmaceuticalIncMembersrt:MinimumMember2021-04-302021-04-300001794783slqt:SimpleMedsMember2021-08-310001794783slqt:SimpleMedsMember2021-08-312021-08-310001794783slqt:SeniorSegmentMemberslqt:SimpleMedsMember2023-06-300001794783us-gaap:ComputerEquipmentMember2023-09-300001794783us-gaap:ComputerEquipmentMember2023-06-300001794783us-gaap:EquipmentMember2023-09-300001794783us-gaap:EquipmentMember2023-06-300001794783us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-09-300001794783us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-06-300001794783us-gaap:FurnitureAndFixturesMember2023-09-300001794783us-gaap:FurnitureAndFixturesMember2023-06-300001794783us-gaap:ConstructionInProgressMember2023-09-300001794783us-gaap:ConstructionInProgressMember2023-06-300001794783us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-09-300001794783us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300001794783us-gaap:InProcessResearchAndDevelopmentMember2023-09-300001794783us-gaap:InProcessResearchAndDevelopmentMember2023-06-3000017947832022-04-012022-06-300001794783us-gaap:CustomerRelationshipsMember2023-09-300001794783us-gaap:CustomerRelationshipsMember2023-06-300001794783us-gaap:TradeNamesMember2023-09-300001794783us-gaap:TradeNamesMember2023-06-300001794783us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-09-300001794783us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-06-300001794783us-gaap:NoncompeteAgreementsMember2023-09-300001794783us-gaap:NoncompeteAgreementsMember2023-06-300001794783slqt:VenderRelationshipsMember2023-09-300001794783slqt:VenderRelationshipsMember2023-06-3000017947832022-07-012023-06-300001794783slqt:HealthcareServicesMember2023-09-300001794783slqt:MonacaPennsylvaniaMembersrt:AffiliatedEntityMember2023-06-300001794783slqt:MonacaPennsylvaniaMembersrt:AffiliatedEntityMember2023-09-300001794783slqt:MonacaPennsylvaniaMembersrt:AffiliatedEntityMember2023-07-012023-09-300001794783srt:MinimumMember2023-09-300001794783srt:MaximumMember2023-09-300001794783slqt:SanDiegoCaliforniaAndIndianapolisIndianaMember2022-07-012022-09-300001794783slqt:OverlandParkKansasMember2023-07-312023-07-310001794783slqt:OverlandParkKansasMember2022-07-012023-06-300001794783slqt:OverlandParkKansasMember2023-07-012023-09-300001794783us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-09-300001794783us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-06-300001794783us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2019-11-050001794783us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2021-02-240001794783us-gaap:SecuredDebtMemberslqt:DelayedDrawTermLoanFacilityMemberus-gaap:LineOfCreditMember2021-02-240001794783us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-07-012021-06-300001794783us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-11-0200017947832021-11-020001794783us-gaap:SecuredDebtMemberslqt:DelayedDrawTermLoanFacilityMemberus-gaap:LineOfCreditMember2021-11-020001794783us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-12-230001794783us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-08-250001794783us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-09-300001794783us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-08-260001794783us-gaap:SecuredDebtMemberslqt:DelayedDrawTermLoanFacilityMemberus-gaap:LineOfCreditMember2022-08-262022-08-260001794783slqt:TermLoansMemberus-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2023-09-300001794783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMemberus-gaap:LineOfCreditMember2022-08-260001794783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:LineOfCreditMember2023-07-012023-09-300001794783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:LineOfCreditMember2022-08-262022-08-260001794783us-gaap:BaseRateMemberus-gaap:LineOfCreditMember2022-08-262022-08-260001794783us-gaap:LineOfCreditMember2022-08-262022-08-260001794783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2022-08-260001794783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2022-08-262022-08-260001794783us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2022-08-262022-08-260001794783us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembersrt:MinimumMember2022-08-262022-08-260001794783us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMembersrt:MaximumMember2022-08-262022-08-260001794783us-gaap:InterestRateSwapMember2023-09-300001794783us-gaap:BaseRateMemberus-gaap:InterestRateSwapMember2023-09-300001794783slqt:HartelVSelectQuoteIncMembersrt:ExecutiveOfficerMember2021-08-172021-08-17slqt:defendant0001794783slqt:WestPalmBeachPolicePensionFundVSelectQuoteIncMembersrt:ExecutiveOfficerMember2021-10-072021-10-070001794783slqt:WestPalmBeachPolicePensionFundVSelectQuoteIncMemberslqt:CurrentAndFormerDirectorMember2021-10-072021-10-070001794783us-gaap:CommonStockMemberslqt:EmployeeStockPurchasePlan2020Member2023-09-300001794783us-gaap:CommonStockMemberslqt:A2020PlanMember2023-09-300001794783slqt:A2003PlanMemberus-gaap:CommonStockMember2023-09-300001794783us-gaap:CommonStockMember2023-09-30slqt:plan0001794783slqt:A2020PlanMember2023-07-012023-09-300001794783slqt:IncentiveStockOptionsMemberslqt:A2020PlanMember2023-09-300001794783slqt:IncentiveStockOptionsMember2023-07-012023-09-300001794783slqt:IncentiveStockOptionsMember2022-07-012022-09-300001794783us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001794783us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001794783us-gaap:PerformanceSharesMember2023-07-012023-09-300001794783us-gaap:PerformanceSharesMember2022-07-012022-09-300001794783slqt:PriceVestedUnitsPVUsMember2023-07-012023-09-300001794783slqt:PriceVestedUnitsPVUsMember2022-07-012022-09-300001794783slqt:A2003PlanMember2023-07-012023-09-300001794783slqt:A2003PlanMember2023-09-30slqt:installment0001794783slqt:A2003PlanMember2022-07-012022-09-300001794783us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2023-07-012023-09-300001794783us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-07-012023-09-300001794783us-gaap:RestrictedStockUnitsRSUMember2023-06-300001794783us-gaap:RestrictedStockUnitsRSUMember2023-09-300001794783us-gaap:PerformanceSharesMember2023-06-300001794783us-gaap:PerformanceSharesMember2023-09-300001794783us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-09-130001794783us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-09-132023-09-130001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:PerformanceSharesMember2023-09-30slqt:tranche0001794783slqt:PriceVestedUnitsPVUsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-07-012023-09-300001794783srt:MinimumMemberslqt:PriceVestedUnitsPVUsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-07-012023-09-300001794783slqt:PriceVestedUnitsPVUsMembersrt:MaximumMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMemberslqt:PriceVestedUnitsPVUsMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:MinimumMemberslqt:PriceVestedUnitsPVUsMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMemberslqt:PriceVestedUnitsPVUsMembersrt:MaximumMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheThreeMemberslqt:PriceVestedUnitsPVUsMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheThreeMembersrt:MinimumMemberslqt:PriceVestedUnitsPVUsMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheThreeMemberslqt:PriceVestedUnitsPVUsMembersrt:MaximumMember2023-07-012023-09-300001794783slqt:PriceVestedUnitsPVUsMemberslqt:ShareBasedCompensationAwardTrancheFourMember2023-07-012023-09-300001794783srt:MinimumMemberslqt:PriceVestedUnitsPVUsMemberslqt:ShareBasedCompensationAwardTrancheFourMember2023-07-012023-09-300001794783slqt:PriceVestedUnitsPVUsMembersrt:MaximumMemberslqt:ShareBasedCompensationAwardTrancheFourMember2023-07-012023-09-300001794783slqt:PriceVestedUnitsPVUsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-07-012022-09-300001794783srt:MinimumMemberslqt:PriceVestedUnitsPVUsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-07-012022-09-300001794783slqt:PriceVestedUnitsPVUsMembersrt:MaximumMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-07-012022-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMemberslqt:PriceVestedUnitsPVUsMember2022-07-012022-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:MinimumMemberslqt:PriceVestedUnitsPVUsMember2022-07-012022-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMemberslqt:PriceVestedUnitsPVUsMembersrt:MaximumMember2022-07-012022-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheThreeMemberslqt:PriceVestedUnitsPVUsMember2022-07-012022-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheThreeMembersrt:MinimumMemberslqt:PriceVestedUnitsPVUsMember2022-07-012022-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheThreeMemberslqt:PriceVestedUnitsPVUsMembersrt:MaximumMember2022-07-012022-09-300001794783slqt:PriceVestedUnitsPVUsMemberslqt:ShareBasedCompensationAwardTrancheFourMember2022-07-012022-09-300001794783srt:MinimumMemberslqt:PriceVestedUnitsPVUsMemberslqt:ShareBasedCompensationAwardTrancheFourMember2022-07-012022-09-300001794783slqt:PriceVestedUnitsPVUsMembersrt:MaximumMemberslqt:ShareBasedCompensationAwardTrancheFourMember2022-07-012022-09-300001794783slqt:PriceVestedUnitsPVUsMember2023-06-300001794783slqt:PriceVestedUnitsPVUsMember2023-09-300001794783slqt:EmployeeStockPurchasePlan2020Memberus-gaap:EmployeeStockMember2023-07-012023-09-300001794783slqt:EmployeeStockPurchasePlan2020Memberus-gaap:EmployeeStockMember2022-07-012022-09-300001794783slqt:A2003PlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-07-012023-09-300001794783us-gaap:ShareBasedCompensationAwardTrancheTwoMemberslqt:A2003PlanMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:MedicareAdvantageMemberslqt:SeniorMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:MedicareAdvantageMemberslqt:SeniorMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:MedicareSupplementalMemberslqt:SeniorMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:MedicareSupplementalMemberslqt:SeniorMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMemberslqt:PrescriptionDrugPlanMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMemberslqt:PrescriptionDrugPlanMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMemberslqt:DentalVisionAndHealthMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMemberslqt:DentalVisionAndHealthMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:OtherCommissionRevenueMemberslqt:SeniorMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:OtherCommissionRevenueMemberslqt:SeniorMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMemberus-gaap:ServiceMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMemberus-gaap:ServiceMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:SeniorMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:SeniorMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:SeniorMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:HealthcareServicesMemberslqt:PharmacyMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:HealthcareServicesMemberslqt:PharmacyMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:HealthcareServicesMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:HealthcareServicesMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:HealthcareServicesMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:HealthcareServicesMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:TermMemberslqt:LifeMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:TermMemberslqt:LifeMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:FinalExpenseMemberslqt:LifeMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:FinalExpenseMemberslqt:LifeMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:LifeMemberus-gaap:ServiceMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:LifeMemberus-gaap:ServiceMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:LifeMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:LifeMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:LifeMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:LifeMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:AutoHomeMemberus-gaap:ServiceMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:AutoHomeMemberus-gaap:ServiceMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:AutoHomeMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberus-gaap:ProductAndServiceOtherMemberslqt:AutoHomeMember2022-07-012022-09-300001794783us-gaap:OperatingSegmentsMemberslqt:AutoHomeMember2023-07-012023-09-300001794783us-gaap:OperatingSegmentsMemberslqt:AutoHomeMember2022-07-012022-09-300001794783us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2023-07-012023-09-300001794783us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2022-07-012022-09-300001794783us-gaap:ProductAndServiceOtherMemberus-gaap:IntersegmentEliminationMember2023-07-012023-09-300001794783us-gaap:ProductAndServiceOtherMemberus-gaap:IntersegmentEliminationMember2022-07-012022-09-300001794783us-gaap:IntersegmentEliminationMember2023-07-012023-09-300001794783us-gaap:IntersegmentEliminationMember2022-07-012022-09-300001794783slqt:SeniorSegmentMemberslqt:AutoHomeSegmentMember2023-07-012023-09-300001794783slqt:LifeSegmentMemberslqt:AutoHomeSegmentMember2023-07-012023-09-300001794783us-gaap:RestrictedStockUnitsRSUMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001794783us-gaap:RestrictedStockUnitsRSUMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001794783slqt:PriceVestedUnitsPVUsMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001794783slqt:PriceVestedUnitsPVUsMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001794783us-gaap:PhantomShareUnitsPSUsMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001794783us-gaap:PhantomShareUnitsPSUsMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001794783us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001794783us-gaap:EmployeeStockOptionMember2022-07-012022-09-30slqt:segment0001794783us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001794783us-gaap:CorporateNonSegmentMember2022-07-012022-09-300001794783slqt:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberslqt:SeniorMember2023-07-012023-09-300001794783slqt:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberslqt:SeniorMember2023-07-012023-09-300001794783slqt:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberslqt:SeniorMember2022-07-012022-09-300001794783us-gaap:CustomerConcentrationRiskMemberslqt:MajorCustomerThreeMemberus-gaap:RevenueFromContractWithCustomerMemberslqt:SeniorMember2022-07-012022-09-30

(Commission File Number)

(Exact name of registrant as specified in its charter)

Delaware									94-3339273
(State or other jurisdiction of incorporation or organization)									(I.R.S. Employer Identification No.)
6800 West 115th Street			Suite 2511						66211
Overland Park			Kansas						(Zip Code)
(Address of principal executive offices)

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

SLQT

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒   No  ☐ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes  ☐   No  ☒

The registrant had outstanding 167,733,095 shares of common stock as of October 31, 2023.

Three Months Ended September 30, 2023
			Common Stock												Additional Paid-In Capital						Accumulated Deficit												Accumulated Other Comprehensive Income						Total Shareholders' Equity
			Shares						Amount
BALANCES-June 30, 2023			166,867						$	1,669					$	567,266					$	(235,644)											$	13,679					$	346,970
Net loss																					(31,051)																		(31,051)
Gain on cash flow hedge, net of tax																																	841						841
Amount reclassified into earnings, net tax																																	(2,851)						(2,851)
Vesting of restricted stock unit awards and performance stock unit awards net of shares withheld to cover tax withholdings			864						8						(354)																								(346)
Share-based compensation expense															3,175																								3,175
BALANCES-September 30, 2023			167,731						$	1,677					$	570,087					$	(266,695)											$	11,669					$	316,738

(In thousands)

			Three Months Ended September 30,
			2023						2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss			$	(31,051)					$	(42,484)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization			5,989						6,802
Loss on disposal of property, equipment, and software			9						325
Share-based compensation expense			3,175						2,630
Deferred income taxes			(13,049)						(13,931)
Amortization of debt issuance costs and debt discount			1,612						1,612
Write-off of debt issuance costs			—						710
Accrued interest payable in kind			3,622						1,307
Non-cash lease expense			784						1,103
Changes in operating assets and liabilities:
Accounts receivable, net			38,693						34,770
Commissions receivable			(29,148)						(36,012)
Other assets			(2,027)						1,271
Accounts payable and accrued expenses			5,257						(10,496)
Operating lease liabilities			(1,498)						(1,256)
Other liabilities			(6,039)						6,479
Net cash used in operating activities			(23,671)						(47,170)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(616)						(298)
Proceeds from sales of property and equipment			253						—
Purchases of software and capitalized software development costs			(1,782)						(2,087)
Net cash used in investing activities			(2,145)						(2,385)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on Term Loans			(8,471)						(8,917)
Payments on other debt			(37)						(44)
Proceeds from common stock options exercised and employee stock purchase plan			—						1,079
Payments of tax withholdings related to net share settlement of equity awards			(346)						(32)
Payments of debt issuance costs			—						(10,110)
Payment of acquisition holdback			—						(2,335)
Net cash used in financing activities			(8,854)						(20,359)
NET DECREASE IN CASH AND CASH EQUIVALENTS			(34,670)						(69,914)
CASH AND CASH EQUIVALENTS—Beginning of period			83,156						140,997
CASH AND CASH EQUIVALENTS—End of period			$	48,486					$	71,083

SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid, net			$	(17,927)					$	(13,026)
Income taxes paid			(142)						(7)

1.SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business—SelectQuote, Inc. (together with its subsidiaries, the “Company” or “SelectQuote”) is a leading technology-enabled, direct-to-consumer distribution platform for insurance products and healthcare services. We contract with insurance carriers to sell senior health, life, and auto and home insurance policies by telephone to individuals throughout the United States through the use of multi-channel marketing and advertising campaigns. SelectQuote’s Senior division (“Senior”) sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote’s Life division (“Life”) sells term life, final expense, and other ancillary products, and SelectQuote’s Auto & Home division (“Auto & Home”) primarily sells non-commercial auto and home, property and casualty insurance products. The Healthcare Services division (“Healthcare Services”) includes SelectRx and Population Health. SelectRx is a Patient-Centered Pharmacy Home™ (“PCPH”) accredited pharmacy, which offers essential prescription medications, OTC medications, customized medication packaging, and medication therapy management, providing long-term pharmacy care that enables patients to optimize medication adherence to drive positive health outcomes while enabling patients to remain at home. Population Health helps members understand the benefits available under their health plans, contracts with insurance carriers to complete HRA’s on members, partners with value-based care (“VBC”) providers for a variety of healthcare-related services, and introduces members to the pharmacy services offered through SelectRx

Basis of Presentation—The accompanying unaudited condensed consolidated financial statements include the accounts of SelectQuote, Inc. and its wholly owned subsidiaries: SelectQuote Insurance Services, SelectQuote Auto & Home Insurance Services, LLC, ChoiceMark Insurance Services, Inc., Tiburon Insurance Services, InsideResponse, LLC (“InsideResponse”), and SelectQuote Ventures, Inc. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended June 30, 2023, filed with the Securities and Exchange Commission on September 13, 2023 (the “Annual Report”), and include all adjustments necessary for the fair presentation of our financial position for the periods presented. Our results for the periods presented in our financial statements are not necessarily indicative of the results to be expected for any subsequent period, including for the year ending June 30, 2024, and therefore should not be relied upon as an indicator of future results. The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2023.

Use of Estimates—The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities. The Company regularly assesses these estimates; however, actual amounts could differ from those estimates. The most significant items involving management’s estimates include estimates of revenue recognition, accounts receivable, net, commissions receivable, the provision for income taxes, share-based compensation, and valuation of intangible assets and goodwill. The impact of changes in estimates is recorded in the period in which they become known.

Seasonality—Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year during the Medicare annual enrollment period (“AEP”) in October through December and are allowed to switch plans from an existing plan during the open enrollment period (“OEP”) in January through March each year.

As a result, the Company’s Senior segment’s commission revenue is highest in the second quarter and to a lesser extent, the third quarter during OEP.

Significant Accounting Policies—There have been no material changes to the Company’s significant accounting policies as described in our Annual Report.

Recent Accounting Pronouncements Adopted—The Company did not adopt any new accounting pronouncements during the three months ended September 30, 2023.

2.ACQUISITIONS

In accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”), the Company allocates the fair value of purchase consideration to the tangible assets, liabilities, and intangible assets acquired based on fair values. Any excess purchase price over those fair values is recorded as goodwill. The fair value assigned to intangible assets acquired is supported by valuations using estimates and assumptions provided by management. Based on the valuation inputs, the Company has recorded assets acquired and liabilities assumed according to the following fair value hierarchy:

Express Med Pharmaceuticals—On April 30, 2021, the Company acquired 100% of the outstanding shares of Express Med Pharmaceuticals, Inc., which is included in SelectRx, a closed-door, long term care pharmacy provider, for an aggregate purchase price of up to $24.0 million, as set forth in the Stock Purchase Agreement dated April 30, 2021 (the “Stock Purchase Agreement”). The aggregate purchase price of up to $24.0 million is comprised of $17.5 million in cash paid at the closing of the transaction, an additional $2.5 million of holdback for indemnification claims, if any, and an earnout of up to $4.0 million, if any. The earnout of up to $4.0 million is comprised of two separate provisions. During the year ended June 30, 2023, the Company paid the first and second earnout provisions of $3.0 million and $1.0 million, respectively, as well as the remaining holdback, net of adjustments, of $2.4 million. At the date of acquisition, the fair value of net tangible assets acquired, excluding property and equipment, approximated their carrying value. The property and equipment was valued primarily using the cost and sales comparison approach to value. For the proprietary software acquired, the replacement cost method under the cost approach was used, estimating the cost to rebuild the software. The non-compete agreement was valued using the income approach, and the customer relationships were valued using the multiple period excess earnings method. As such, all aforementioned intangible assets were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the SelectRx business with the Company's technology and existing customer base. This acquired goodwill is allocated to the Healthcare Services reporting unit, which is also a reportable segment, and $16.3 million is deductible for tax purposes after adding back acquisition costs and settling the remaining holdback. The Company is amortizing the intangible assets acquired on a straight-line basis over their estimated remaining lives, ranging from one to five years.    

Simple Meds—On August 31, 2021, SelectRx acquired 100% of the outstanding equity interests of Simple Meds, a full-service pharmaceutical distributor, for an aggregate purchase price of $7.0 million, as set forth in the Membership Interest Purchase Agreement dated August 31, 2021. The aggregate purchase price of $7.0 million was paid in cash at the closing of the transaction. At the date of acquisition, the fair value of net tangible assets acquired approximated their carrying value. The customer relationships were valued using the multiple period excess earnings method, and as such, were valued using Level 3 inputs. Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the Simple Meds business with the Company's technology and existing customer base.

This acquired goodwill is allocated to the Healthcare Services reporting unit, which is also a reportable segment, and $5.6 million is deductible for tax purposes after adding back acquisition costs.

3.PROPERTY AND EQUIPMENT—NET

Property and equipment—net consisted of the following:

(1) Includes financing lease right-of-use assets.

Work in progress as of September 30, 2023 primarily represents computer equipment held for sale and leasehold improvements not yet put into service and not yet being depreciated. Work in progress as of June 30, 2023, primarily represents leasehold improvements and computer equipment not yet put into service and not yet being depreciated. Depreciation expense for the three months ended September 30, 2023 and 2022, was $3.2 million and $3.5 million, respectively.

4.SOFTWARE—NET

Software—net consisted of the following:

Work in progress as of September 30, 2023 and June 30, 2023, represents costs incurred for software not yet put into service and not yet being amortized. For each of the three months ended September 30, 2023 and 2022, the Company capitalized internal-use software and website development costs of $2.0 million and recorded amortization expense of $2.1 million and $1.8 million, respectively.

5.INTANGIBLE ASSETS AND GOODWILL

Intangible assets—The carrying amounts, accumulated amortization, and net carrying value of our definite-lived intangible assets are presented in the table below (dollars in thousands):

(1) During the year ended June 30, 2023, the Company recorded impairment charges for its long-lived intangible assets recognized as part of the acquisition of a lead distribution company. Refer to the consolidated financial statements in our Annual Report on Form 10-K for additional details.

The Company's intangible assets include those long-lived intangible assets which were recognized at their estimated acquisition date fair values. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. There were no impairment triggers identified with respect to the Company’s long-lived assets during the three months ended September 30, 2023 and 2022.

For the three months ended September 30, 2023 and 2022, amortization expense related to intangible assets totaled $0.8 million and $1.5 million, respectively, recorded in selling, general, and administrative expense in the condensed consolidated statements of comprehensive loss. The weighted-average remaining useful life of intangible assets was 3.3 and 3.6 years as of September 30, 2023 and June 30, 2023, respectively.

As of September 30, 2023, expected amortization expense in future fiscal periods were as follows (in thousands):

Goodwill—The Company recorded as goodwill the excess of the purchase price over the estimated fair values of identifiable assets and liabilities acquired as part of the acquisitions discussed in Note 2 to the condensed consolidated financial statements. Goodwill is assigned to reporting units that are expected to benefit from the synergies of the business combination as of the acquisition date and becomes identified with that reporting unit in its entirety. As such, the reporting unit as a whole supports the recovery of its goodwill. As of September 30, 2023, the Company’s goodwill balance of $29.1 million was related to the acquisitions of Express Meds and Simple Meds and is all assigned to the Healthcare Services reporting unit and reportable segment.

The Company performs its annual goodwill impairment testing as of April 1, or more frequently if it believes that indicators of impairment exist. During the three months ended September 30, 2023 and 2022, there were no indicators of impairment.

6.LEASES

The majority of the Company’s leases are operating leases related to office space for which the Company recognizes lease expense on a straight-line basis over the respective lease term.

The Company leases office facilities in the United States in San Diego, California; Centennial, Colorado; Overland Park, Kansas; Oakland, California; Indianapolis, Indiana; and Monaca, Pennsylvania (note that SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise). The Company's operating leases have remaining lease terms from one year up to thirteen years.

During the three months ended September 30, 2022, operating leases commenced in San Diego, California and Indianapolis, Indiana, resulting in new right-of-use assets obtained in exchange for new lease liabilities of $1.6 million. In addition, the Company exercised an early termination option for a portion of its office facilities in Overland Park, Kansas, with a new termination date of July 31, 2023, resulting in an early termination penalty of $0.9 million, of which $0.6 million was paid during the year ended June 30, 2023, and $0.3 million was paid during the three months ended September 30, 2023. The early termination penalty was recorded as part of the remeasurement of the operating lease liability and resulted in accelerated amortization of the right-of-use asset over the shortened remaining term of the lease.

Lease Costs—The components of lease costs were as follows for the periods presented:

(1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income.

(2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income.

(3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income.

Maturities of Lease Liabilities—As of September 30, 2023, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows:

The Company executed noncancelable subleases for portions of its office facilities in Overland Park, Kansas and Centennial, Colorado, which commenced during the fiscal years ended June 30, 2023 and 2022, and run through the remaining terms of the primary leases.

Sublease income is recorded on a straight-line basis as a reduction of lease expense in the condensed consolidated statements of comprehensive income. The Company may consider entering into additional sublease arrangements in the future.

Sublease Income—As of September 30, 2023, the future minimum fixed sublease receipts under non-cancelable operating lease agreements are as follows:

7.DEBT

Debt consisted of the following:

Senior Secured Credit Facility— On November 5, 2019, the Company entered into a $425.0 million credit agreement with UMB Bank N.A. (“UMB”) as a lender and revolving agent and Morgan Stanley Capital Administrators, Inc. as a lender and the administrative agent for a syndicate of lenders party to the agreement (replaced by Wilmington Trust as administrative agent effective February 24, 2022). On February 24, 2021, November 2, 2021, December 23, 2021, August 26, 2022, May 5, 2023, and September 11, 2023, the Company entered into amendments to the credit agreement (individually, the “First Amendment”, “Second Amendment”, “Third Amendment”, “Fourth Amendment”, “Fifth Amendment”, and “Sixth Amendment”, together with the original credit agreement and any subsequent amendments, the “Senior Secured Credit Facility”) with certain of its existing lenders and new lenders. The First Amendment provided for an additional $231.0 million in term loans (together with the initial $425.0 million, the “Term Loans”) and added a $145.0 million senior secured delayed draw term loan facility (the "DDTL Facility"). The Company recognized a $3.3 million loss on debt extinguishment in the condensed consolidated statement of comprehensive income (loss) for the year ended June 30, 2021, as part of the First Amendment. The Second Amendment provided for additional commitments of $25.0 million, in addition to the initial $75.0 million, for the secured revolving loan facility (the “Revolving Credit Facility”) and an additional $200.0 million under the DDTL Facility. The Third Amendment provided for additional commitments of $35.0 million under the Revolving Credit Facility. The Fourth Amendment (1) amended the Company’s existing financial covenant to better align with its business plan and added an additional minimum liquidity covenant, (2) terminated certain DDTL commitments and reduced the Revolving Credit Facility from $135.0 million to $100.0 million, (3) introduced a minimum asset coverage ratio for any borrowing on the Revolving Credit Facility that would result in a total revolving exposure of more than $50.0 million, and (4) provided certain lenders with the right to appoint a representative to observe meetings of the Company’s board of directors and certain of its committees. In addition, the Fourth Amendment provided for the Company to pay a revolving credit termination fee of $0.5 million for the ratable account of each revolving lender upon the termination of all revolving loan commitments.

Note that pursuant to the Fourth Amendment, upon termination of the outstanding DDTL commitments, when referring to Term Loans, it will now include the outstanding balance of the previously defined Term Loans and also the outstanding balance of the DDTL, and “DDTL” will no longer be referenced. The Fifth Amendment decreased the minimum asset coverage ratio required to be maintained by the Company as of March 31, 2024, and the Sixth Amendment decreased the minimum asset coverage ratio required to be maintained by the Company as of June 30, 2024. After giving effect to the amendments, in aggregate, the Senior Secured Credit Facility provides for (1) an aggregate principal amount of up to $100.0 million under the Revolving Credit Facility, of which all was available to borrow as of September 30, 2023 and (2) Term Loans outstanding in an aggregate principal amount of $702.7 million as of September 30, 2023.

The Term Loans bear interest on the outstanding principal amount thereof at a rate per annum equal to either (a) SOFR (subject to a floor of 0.75%) plus 6.00% in cash plus 2.00% payable in kind or (b) a base rate plus 5.00% in cash plus 2.00% payable in kind, at the Company’s option. As of October 1, 2023, the cash and paid in kind interest rate with respect to the Term Loans increased 0.50% and 1.00%, respectively. The Revolving Credit Facility accrues interest on amounts drawn at a rate per annum equal to either (a) SOFR (subject to a floor of 1.0%) plus 5.0% or (b) a base rate plus 4.0%, at the Company’s option.

The Senior Secured Credit Facility has a maturity date of November 5, 2024, and the Term Loans are mandatorily repayable in equal quarterly installments in an aggregate annual amount equal to 2.5% of the outstanding principal amount of the Term Loans as of the Fourth Amendment effective date, which increased to 4.75% on July 1, 2023, with the remaining balance payable on the maturity date. As of September 30, 2023, the Company has made principal payments of $214.0 million on the Term Loans.

The Senior Secured Credit Facility contains customary affirmative and negative covenants and events of default and financial covenants requiring the Company and certain of its subsidiaries to maintain a minimum asset coverage ratio and minimum liquidity requirements. As of September 30, 2023, the Company was in compliance with all of the required covenants. The obligations of the Company are guaranteed by the Company’s subsidiaries and secured by a security interest in all assets of the Company, subject to certain exceptions.

The Company has incurred a total of $40.1 million in debt issuance costs and debt discounts related to the Senior Secured Credit Facility, of which $33.0 million was capitalized. The costs associated with the Revolving Credit Facility are being amortized on a straight-line basis over the remaining life of the Senior Secured Credit Facility and the costs associated with the Term Loans are being amortized using the effective interest method over the same term. Total amortization of debt issuance costs was $1.6 million for each of the three months ended September 30, 2023 and 2022, which was included in interest expense, net in the Company’s condensed consolidated statements of comprehensive loss.

The Company uses derivative financial instruments to hedge against its exposure to fluctuations in interest rates associated with the Term Loans. On September 30, 2022, as a result of the Fourth Amendment, the Company terminated its existing interest rate swap indexed to 1-month LIBOR and executed a new interest rate swap indexed 1-month SOFR. In accordance with ASC 848, Reference Rate Reform, the Company did not de-designate the interest rate swap when it was amended from LIBOR to SOFR as the Company is permitted to maintain the designation as part of the transitional relief. As of September 30, 2023, the Company’s interest rate swap is a receive-variable, pay-fixed interest rate swap on the notional amount of $325.0 million of the Company’s total outstanding Term Loans balance with a fixed rate of 6.00% plus 0.931% (the “Amended Interest Rate Swap”), which terminates on November 5, 2024. As of September 30, 2023, the Amended Interest Rate Swap had a fair value of $15.4 million and was recorded in other assets in the condensed consolidated balance sheet. The Company classifies its Amended Interest Rate Swap as a Level 2 on the fair value hierarchy as the majority of the inputs used to value it primarily includes other than quoted prices that are observable and it uses standard calculations and models that use readily observable market data as their basis. The Company estimates that $14.1 million will be reclassified into interest expense during the next twelve months.

8.COMMITMENTS AND CONTINGENCIES

Lease Obligations—Refer to Note 6 to the condensed consolidated financial statements for commitments related to our operating leases.

Legal Contingencies and Obligations—From time to time, the Company is subject to legal proceedings and governmental inquiries in the ordinary course of business. Such matters may include insurance regulatory claims; commercial, tax, employment, or intellectual property disputes; matters relating to competition and sales practices; claims for damages arising out of the use of the Company’s services. The Company may also become subject to lawsuits related to past or future acquisitions, divestitures, or other transactions, including matters related to representations and warranties, indemnities, and assumed or retained liabilities. The Company is not currently aware of any legal proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition, operating results, or cash flows; however, in the event of unexpected developments, it is possible that the ultimate resolution of certain ongoing matters, if unfavorable, could be materially adverse to our business, prospects, financial condition, liquidity, results of operation, cash flows, or capital levels.

On August 17, 2021, a putative securities class action lawsuit captioned Hartel v. SelectQuote, Inc., et al., Case No. 1:21-cv-06903 (“the Hartel Action”) was filed against the Company and two of its executive officers in the U.S. District Court for the Southern District of New York. The complaint asserts securities fraud claims on behalf of a putative class of plaintiffs who purchased or otherwise acquired shares of the Company’s common stock between February 8, 2021 and May 11, 2021 (the "Hartel Relevant Period"). Specifically, the complaint alleges the defendants violated Sections 10(b) and 20(a) and Rule 10b-5 of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company’s business, operations, and prospects, allegedly causing the Company’s common stock to trade at artificially inflated prices during the Hartel Relevant Period. The plaintiffs seek unspecified damages and reimbursement of attorneys’ fees and certain other costs.

On October 7, 2021, a putative securities class action lawsuit captioned West Palm Beach Police Pension Fund v. SelectQuote, Inc., et al., Case No. 1:21-cv-08279 (“the WPBPPF Action”), was filed in the U.S. District Court for the Southern District of New York against the Company, two of its executive officers, and six current or former members of the Company’s Board of Directors, along with the underwriters of the Company’s initial public offering of common stock (the "Offering"). The complaint asserts claims for securities law violations on behalf of a putative class of plaintiffs who purchased shares of the Company’s common stock (i) in or traceable to the Offering or (ii) between May 20, 2020 and August 25, 2021 (the "WPB Relevant Period"). Specifically, the complaint alleges the defendants violated Sections 10(b) and 20(a) and Rule 10b-5 of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company’s financial well-being and prospects, allegedly causing the Company’s common stock to trade at artificially inflated prices during the WPB Relevant Period. The complaint also alleges the defendants violated Sections 11, 12(a)(2), and 15 of the Securities Act by making misstatements and omissions of material facts in connection with the Offering, allegedly causing a decline in the value of the Company’s common stock. The plaintiffs seek unspecified damages, rescission, and reimbursement of attorneys’ fees and certain other costs. On October 15, 2021, a motion to consolidate the Hartel Action and the WPBPPF Action (together, the “Securities Class Actions”) was filed. Certain plaintiffs and their counsel have moved to be appointed lead plaintiff. Those motions are pending before the court.

On March 25, 2022, a stockholder derivative action captioned Jadlow v. Danker, et al., Case No. 1:22-cv-00391 (“the Jadlow Action”) was filed in the U.S. District Court for the District of Delaware by an alleged stockholder of the Company, purportedly on the Company’s behalf. The lawsuit was brought against certain of the Company’s current and former directors and officers, and against the Company, as nominal defendant. The complaint alleges that certain of the defendants violated Section 14(a) of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company’s business, operations, and prospects. The complaint also asserts claims against all defendants for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets based on the same general underlying conduct and seeks contribution under Sections 10(b) and 21D of the Exchange Act and Section 11(f) of the Securities Act from the individual defendants named in the Securities Class Actions. The complaint seeks unspecified damages for the Company, restitution, reformation and improvement of its corporate governance and internal procedures regarding compliance with laws, and reimbursement of costs and attorneys’ fees. On July 25, 2022, the Jadlow action was transferred to the U.S. District Court for the Southern District of New York, where it was assigned Case No. 1:22-cv-06290 and referred to Judge Alvin K. Hellerstein as possibly related to the Hartel Action. On August 4, 2022, Judge Hellerstein accepted the Jadlow action as related to the Hartel Action and, on August 10, 2022, granted the parties’ joint stipulation to stay the Jadlow action pending the resolution of an anticipated motion to dismiss the Securities Class Actions.

The Company currently believes that these matters will not have a material adverse effect on any of its results of operations, financial condition or liquidity; however, depending on how the matters progress, they could be costly to defend and could divert the attention of management and other resources from operations. The Company has not concluded that a loss related to these matters is probable and, therefore, has not accrued a liability related to these matters.

9.SHAREHOLDERS' EQUITY

Common Stock—As of September 30, 2023, the Company has reserved the following authorized, but unissued, shares of common stock:

The Company has awards outstanding from two share-based compensation plans: the 2003 Stock Incentive Plan (the “2003 Stock Plan”) and the 2020 Omnibus Incentive Plan (the “2020 Stock Plan” and, collectively with the 2003 Stock Plan, the “Stock Plans”). However, no further awards will be made under the 2003 Stock Plan. The Company's Board of Directors adopted, and shareholders approved, the 2020 Stock Plan in connection with the Company’s IPO, which provides for the grant of incentive stock options (“ISO's”), nonstatutory stock options (“NSO's”), stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSU's”), performance-based restricted stock units (“PSU's”), price-vested restricted stock units (“PVU’s”), and other forms of equity compensation (collectively, “stock awards”). All stock awards (other than ISOs, which may be granted only to current employees of the Company) may be granted to employees, non-employee directors, and consultants of the Company and its subsidiaries and affiliates.

The number of shares of common stock available for issuance as of September 30, 2023, pursuant to future awards under the Company's 2020 Stock Plan is 3,271,623. The number of shares of the Company's common stock reserved under the 2020 Stock Plan is subject to an annual increase on the first day of each fiscal year, beginning on July 1, 2021, equal to 3% of the total outstanding shares of common stock as of the last day of the immediately preceding fiscal year.

The maximum number of shares of common stock that may be issued upon the exercise of ISO's will be 4,000,000. The shares of common stock covered by any award that is forfeited, terminated, expired, or lapsed without being exercised or settled for cash will again become available for issuance under the 2020 Stock Plan. With respect to any award, if the exercise price and/or tax withholding obligations are satisfied by delivering shares to the Company (by actual delivery or attestation), or if the exercise price and/or tax withholding obligations are satisfied by withholding shares otherwise issuable pursuant to the award, the share reserve shall nonetheless be reduced by the gross number of shares subject to the award.

The Company accounts for its share-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation (“ASC 718”) which requires all share-based compensation to be recognized in the income statement based on fair value and applies to all awards granted, modified, canceled, or repurchased after the effective date.

Total share-based compensation for stock awards included in selling, general, and administrative expense in the condensed consolidated statements of comprehensive income was as follows for the periods presented:

Stock Options—The stock options outstanding under the 2003 Stock Plan vest as to one-third after the vesting commencement date and as to 1/24 of the remaining shares subject to the stock option monthly thereafter, subject to the award recipient’s continued employment through the applicable vesting date. Upon a termination of employment for any reason other than for “Cause” (as defined in the 2003 Stock Plan), any unvested and outstanding stock options would generally be forfeited for no consideration, and any vested and outstanding stock options would remain exercisable for 90 days following the date of termination (and, in the case of a termination of employment due to death or disability, for 12 months following the date of termination). Stock options expire 10 years from the date of grant. The terms for ISO's and NSO's awarded in the 2020 Stock Plan are the same as in the 2003 Stock Plan with the exception that the options generally shall vest and become exercisable in four equal installments on each of the first four anniversaries of the grant date, subject to the award recipient’s continued employment through the applicable vesting date. Stock options are granted with an exercise price that is no less than 100% of the fair market value of the underlying shares on the date of the grant.

The fair value of each option (for purposes of calculation of share-based compensation expense) is estimated using the Black-Scholes-Merton option pricing model that uses assumptions determined as of the date of the grant. Use of this option pricing model requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (“expected term”), the estimated volatility of the Company's common stock price over the expected term (“volatility”), the number of options that will ultimately not complete their vesting requirements (“assumed forfeitures”), the risk-free interest rate that reflects the interest rate at grant date on zero-coupon United States governmental bonds that have a remaining life similar to the expected term (“risk-free interest rate”), and the dividend yield assumption which is based on the Company's dividend payment history and management's expectations of future dividend payments (“dividend yield”). Changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation and, consequently, the related amount recognized in the condensed consolidated statements of comprehensive loss.

During the three months ended September 30, 2023 and 2022, there were no stock options granted. The following table summarizes stock option activity under the Stock Plans for the three months ended September 30, 2023:

As of September 30, 2023, there was $4.2 million in unrecognized compensation cost related to unvested stock options granted, which is expected to be recognized over a weighted-average period of 1.72 years.

During the three months ended September 30, 2023, there were no stock options exercised. The Company received cash of $0.6 million in connection with stock options exercised during the three months ended September 30, 2022.

Restricted Stock—The Company grants RSU's to eligible employees, non-employee directors, and contractors. These awards generally vest over a period of one to four years. Fair value of the RSU's is determined based on the market price of the Company’s common stock at the grant date and share-based compensation expense is recognized over the requisite service period.

The following table summarizes restricted stock unit activity under the 2020 Stock Plan for the three months ended September 30, 2023:

As of September 30, 2023, there was $15.5 million of unrecognized compensation cost related to unvested restricted stock units granted, which is expected to be recognized over a weighted-average period of 2.31 years.

Performance Stock—The following table summarizes performance stock unit activity under the 2020 Stock Plan for the three months ended September 30, 2023:

(1) Represents adjustments to previously granted PSU’s to reflect changes in estimates of future financial performance against targets.

If certain performance metrics are met, PSU’s vest at the end of a three-year performance period. The fiscal year 2021 tranche vested on September 13, 2023, at 13% of the target and 14,477 shares were issued. The number of shares that could be earned for the fiscal year 2022 tranche is estimated to be at 0% of the target as of September 30, 2023. As such, as of September 30, 2023, there was no unrecognized compensation cost related to unvested performance stock units granted.

Price-Vested Units—The Company grants PVU's to eligible employees for which vesting is subject to the fulfillment of both a service period and the achievement of stock price hurdles during the relevant performance period. The awards are divided into four separate tranches, each with a different price hurdle which is measured as the average trading price over 60 calendar days on a rolling daily basis, over a performance period of five years. An employee is eligible to vest in one-third of the awards in each tranche after each year of service, but subject to the achievement of the stock-price hurdle attached to each tranche. As a result, share-based compensation will be recognized on a straight-line basis across twelve tranches over each tranche’s requisite service period, which is the greater of the derived service period and the explicit service period.

The following table summarizes the number of shares, stock price hurdles, service periods, and performance periods for each tranche, for the PVU’s awarded during the three months ended September 30, 2023:

The following table summarizes the number of shares, stock price hurdles, service periods, and performance periods for each tranche, for the PVU’s awarded during the three months ended September 30, 2022:

The fair value of each PVU (for purposes of calculation of share-based compensation expense) is estimated using a Monte Carlo simulation valuation model that uses assumptions determined as of the date of the grant. Use of this model requires the input of subjective assumptions and changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation recognized in the consolidated statements of comprehensive loss. These assumptions include estimating the volatility of the Company's common stock price over the expected term, the risk-free interest rate that reflects the interest rate at grant date on zero-coupon United States governmental bonds that have a remaining life similar to the expected term risk-free interest rate, the cost of equity, and the dividend yield assumption which is based on the Company's dividend payment history and management's expectations of future dividend payments.

The Company used the following weighted-average assumptions for the PVU’s granted during the period presented below:

The following table summarizes price-vested stock unit activity under the 2020 Stock Plan for the three months ended September 30, 2023:

As of September 30, 2023, there was $6.0 million of unrecognized compensation cost related to unvested PVU’s granted, which is expected to be recognized over a weighted-average period of 1.84 years.

ESPP—The purpose of the Company’s employee stock purchase plan (“ESPP”) is to provide the Company's eligible employees with an opportunity to purchase shares on the exercise date at a price equal to 85% of the fair market value of the Company’s common stock as of either the exercise date or the first day of the relevant offering period, whichever is lesser. The ESPP was suspended effective April 1, 2023, and as of September 30, 2023, there are 159 shares reserved for future issuance under the plan. During the three months ended September 30, 2022, the Company issued 779,946 shares to its employees and received cash of $0.5 million in connection with ESPP purchases and recorded share-based compensation expense of $0.2 million.

10.REVENUES FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Revenue from Contracts with Customers—The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance:

Contract Balances—The Company has contract assets related to commissions receivable from its insurance carrier partners, with the movement over time as the policy is renewed between long-term and short-term commissions receivable and accounts receivable, net being the main activity, along with commission revenue adjustments from changes in estimates.

A roll forward of commissions receivable (current and long-term) is shown below for the period presented:

For the three months ended September 30, 2023, the $0.4 million net commission revenue adjustment from change in estimate includes adjustments related to revenue recognized in prior fiscal years, based on the Company’s reassessment of each of its cohorts’ transaction prices. It includes a negative adjustment of $0.6 million for Senior, a positive adjustment of $0.8 million for Auto & Home, and a positive adjustment of $0.2 million for Life.

The Company’s contract liabilities on the condensed consolidated balance sheets represent unamortized upfront payments received as of September 30, 2023, for commission revenue for which the performance obligations have not yet been met and are anticipated to be recognized over the next twelve months.

A roll forward of contract liabilities (current and long-term) is shown below for the period presented:

11.INCOME TAXES

For the three months ended September 30, 2023 and 2022, the Company recognized income tax benefit of $12.8 million and $13.6 million, respectively, representing effective tax rates of 29.2% and 24.3%, respectively. The differences from the federal statutory tax rate to the effective tax rates for both the three months ended September 30, 2023 and 2022, were primarily related to state income taxes.

As of September 30, 2023 the Company has a valuation allowance of $3.3 million for deferred tax assets related to certain state specific net operating losses and credits, as it is more likely than not that those assets will not be realized. As the Company is currently in a three-year cumulative loss position, it cannot consider the projections of future income as part of the valuation allowance analysis and have considered the other sources of future taxable income described under ASC 740 when evaluating the need for a valuation allowance. After evaluating these sources of taxable income, and considering the jurisdiction and character of the deferred tax assets, the Company continues to recognize its deferred tax assets as of September 30, 2023, as it believes it is more likely than not that the net deferred tax assets will be realized, outside of the deferred tax asset related to certain state credits noted above where a valuation allowance has been established.

12.NET LOSS PER SHARE

The Company calculates net loss per share as defined by ASC 260, Earnings per Share (“ASC 260”). Basic net loss per share (“Basic EPS”) is computed by dividing net loss attributable to common shareholders by the weighted-average common stock outstanding during the respective period. Diluted net loss per share (“Diluted EPS”) is computed by dividing net loss attributable to common and common equivalent shareholders by the total of the weighted-average common stock outstanding and common equivalent shares outstanding during the respective period. For the purpose of calculating the Company’s Diluted EPS, common equivalent shares outstanding include common shares issuable upon the exercise of outstanding employee stock options, unvested RSU's, PSU’s assuming the performance conditions are satisfied as of the end of the reporting period, PVU’s assuming market conditions are satisfied as of the end of the reporting period, and common shares issuable upon the conclusion of each ESPP offering period. The number of common equivalent shares outstanding has been determined in accordance with the treasury stock method for employee stock options, RSU's, PSU’s, PVU’s, and common stock issuable pursuant to the ESPP to the extent they are dilutive. Under the treasury stock method, the exercise price paid by the option holder and future share-based compensation expense that the Company has not yet recognized are assumed to be used to repurchase shares.

The following table sets forth the computation of net loss per share for the periods presented:

(1) Excluded from the computation of net loss per share-diluted for the three months ended September 30, 2023 and 2022, because the effect would have been anti-dilutive.

The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted because including them would have been anti-dilutive are as follows for the periods presented:

The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted because the performance or market conditions associated with these awards were not met are as follows for the periods presented:

13.SEGMENT INFORMATION

The Company’s operating and reportable segments have been determined in accordance with ASC 280, Segment Reporting (“ASC 280”). The Company has four reportable segments: i) Senior, ii) Healthcare Services, iii) Life, and iv) Auto & Home. The Company includes non-operating activity, share-based compensation expense, certain intersegment eliminations, and the costs of providing corporate and other administrative services in its administrative division in Corporate & Eliminations. These services and activities are not directly identifiable with the Company’s reportable segments and are shown in the tables below to reconcile the reportable segments to the condensed consolidated financial statements. The Company has not aggregated any operating segments into a reportable segment.

Costs of revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, cost of goods sold, marketing and advertising, technical development, and selling, general, and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; and non-recurring expenses such as severance payments and transaction costs. Our CODM does not separately evaluate assets by segment, with the exception of commissions receivable; therefore, assets by segment are not presented.

The following table presents information about the reportable segments for the three months ended September 30, 2023:

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments, including for lead generation referrals from InsideResponse (within Senior) and referrals between the other segments.

The following table presents information about the reportable segments for the three months ended September 30, 2022:

(in thousands)			Senior						Healthcare Services						Life						Auto & Home						Corp & Elims						Consolidated
Revenue			$	77,513					$	43,067					$	36,835					$	7,082					$	(2,013)		(1)			$	162,484
Operating expenses			(81,366)						(54,854)						(31,811)						(4,640)						(17,446)			(2)			(190,117)
Other income (expense), net			—						—						201						(1)						(42)						158
Adjusted EBITDA			$	(3,853)					$	(11,787)					$	5,225					$	2,441					$	(19,501)					(27,475)
Share-based compensation expense																																	(2,630)
Transaction costs (3)																																	(2,126)
Depreciation and amortization																																	(6,802)
Loss on disposal of property, equipment, and software																																	(325)
Interest expense, net																																	(16,736)
Income tax benefit																																	13,610
Net loss																																	$	(42,484)

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments, including for lead generation referrals from InsideResponse (within Senior) and referrals between the other segments.